Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 11 people enrolled
- Started
- 1 Feb 2025
- Ended
- 30 Jun 2026
- Type of study
- Interventional
- Treatments tested
- 4.5mg daily dose of naltrexone
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Presence of a traumatic cervical or thoracic spinal cord injury
- Age ≥18
- >6 months from time of injury
- Central neuropathic pain related to SCI, based on evaluation of a Physical Medicine \& Rehabilitation Physician
- DN4 questionnaire ≥ 4
- English speaking
Who cannot take part
- Adjustment in pain medications within the previous month
- Current treatment with naltrexone or other opioid antagonist
- Scheduled elective surgery during the duration of the study
- Allergy to naltrexone
- Chronic opioid treatment
- Central neuropathic pain attributed to other etiology
- Neuropathic pain attributed to the peripheral nervous system
- PHQ9 ≥15 indicating moderately severe or severe depressive symptoms
- Documented traumatic brain injury that would affect study participation, in the opinion of the investigator
- Pregnant or breastfeeding
- Illicit substance use per Wisconsin law
Where in United States
- Medical College of WisconsinMilwaukee, United States
About the trial
What the trial wants to find out
The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury.
Read full original descriptionShow less
Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools
There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial.
Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.
The group in the trial
- Low Dose NaltrexoneTreatment being tested
Daily dose of 4.5mg of naltrexone
Treatment: 4.5mg daily dose of naltrexone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low Dose Naltrexone in the Treatment of Central Neuropathic Pain After Traumatic Spinal Cord Injury: A Pilot Study
- Record updated
- 2 November 2026